Voriconazole_NP Inhibition_NP of_IN the_DT Metabolism_NN of_IN Tacrolimus_NP in_IN a_DT Liver_NP Transplant_NP Recipient_NP and_CC in_IN Human_NP Liver_NP Microsomes_NP The_DT purpose_NN of_IN this_DT study_NN was_VBD to_TO assess_VB the_DT effect_NN of_IN voriconazole_NN on_IN the_DT blood_NN tacrolimus_NN concentration_NN in_IN a_DT liver_NN transplant_NN recipient_NN and_CC to_TO examine_VB the_DT interaction_NN between_IN voriconazole_NN and_CC tacrolimus_NN by_IN using_VBG human_JJ liver_NN microsomes_NNS ._SENT Two_CD subjects_NNS were_VBD enrolled_VBN in_IN the_DT clinical_JJ study_NN :_: one_PP received_VBD voriconazole_NN ,_, and_CC the_DT other_JJ received_VBD a_DT placebo_NN ._SENT Tacrolimus_NP metabolism_NN was_VBD evaluated_VBN in_IN human_JJ liver_NN microsomes_NNS at_IN various_JJ concentrations_NNS in_IN the_DT absence_NN and_CC presence_NN of_IN various_JJ concentrations_NNS of_IN voriconazole_NN ._SENT Coadministration_NN of_IN voriconazole_NN and_CC tacrolimus_NN resulted_VBN in_IN elevated_JJ (_( nearly_RB 10-fold-higher_JJ )_) trough_NN tacrolimus_NN blood_NN concentrations_NNS in_IN the_DT liver_NN transplant_NN patient_NN ._SENT In_IN the_DT in_IN vitro_NN study_NN ,_, voriconazole_NN at_IN a_DT concentration_NN of_IN 10.4_CD +-_NN 4.3_CD mug/ml_NN inhibited_VBD the_DT metabolism_NN of_IN tacrolimus_NN by_IN 50_CD %_NN ._SENT Clinically_RB relevant_JJ concentrations_NNS of_IN voriconazole_NN inhibited_VBD the_DT metabolism_NN of_IN tacrolimus_NN in_IN human_JJ liver_NN microsomes_NNS ._SENT Close_JJ monitoring_NN of_IN the_DT blood_NN concentration_NN and_CC adjustment_NN in_IN the_DT dose_NN of_IN tacrolimus_NNS are_VBP warranted_VBN in_IN transplant_NN recipients_NNS treated_VBN with_IN voriconazole_NN ._SENT Organ_NN transplant_NN patients_NNS are_VBP susceptible_JJ to_TO invasive_JJ fungal_JJ infections_NNS that_WDT necessitate_VBP treatment_NN with_IN antifungal_JJ agents_NNS including_VBG the_DT azoles_NNS ._SENT Azole_NN antifungal_NN agents_NNS ,_, e.g._FW ,_, ketoconazole_NN ,_, itraconazole_NN ,_, and_CC fluconazole_NN ,_, are_VBP known_VBN to_TO inhibit_VB the_DT metabolism_NN of_IN immunosuppressive_JJ drugs_NNS such_JJ as_IN cyclosporine_NN and_CC tacrolimus_NN ._SENT Voriconazole_NP is_VBZ a_DT triazole_NN antifungal_JJ agent_NN that_WDT is_VBZ currently_RB undergoing_VBG phase_NN III_NP clinical_JJ trials_NNS for_IN the_DT treatment_NN of_IN a_DT variety_NN of_IN fungal_JJ infections_NNS ._SENT Voriconazole_NP is_VBZ 4-_CD to_TO 16-fold_NN more_RBR active_JJ than_IN fluconazole_NN and_CC 2-_CD to_TO 8-fold_NN more_RBR active_JJ than_IN itraconazole_NN against_IN Candida_NP species_NNS ,_, including_VBG C._NP krusei_NP and_CC C._NP glabrata_NNS ._SENT Voriconazole_NP is_VBZ active_JJ against_IN a_DT wide_JJ range_NN of_IN filamentous_JJ fungi_NNS including_VBG Aspergillus_NP species_NNS ._SENT In_IN a_DT randomized_VBN trial_NN ,_, voriconazole_NN was_VBD more_RBR effective_JJ than_IN amphotericin_NP B_NP as_IN primary_JJ therapy_NN for_IN the_DT treatment_NN of_IN invasive_JJ aspergillosis_NN (_( R._NP Herbrecht_NP et_FW al._FW ,_, Abstr_NP ._SENT 41st_NP Intersci_NP ._SENT Conf_NP ._SENT Antimicrob_NN ._SENT Agents_NPS Chemother_NP ._SENT ,_, abstr_NP ._SENT J-680_NP ,_, p._NN 378_CD ,_, 2001_CD )_) ._SENT Voriconazole_NP also_RB appears_VBZ to_TO be_VB a_DT promising_JJ agent_NN for_IN the_DT treatment_NN of_IN mycelial_JJ fungi_NNS that_WDT either_RB are_VBP innately_RB resistant_JJ or_CC respond_VB erratically_RB to_TO amphotericin_NP B_NP ,_, such_JJ as_IN hyaline_JJ molds_NNS and_CC dematiaceous_JJ fungi_NNS ._SENT Availability_NN in_IN an_DT intravenous_JJ and_CC a_DT highly_RB bioavailable_JJ oral_JJ formulation_NN renders_NNS voriconazole_VBP a_DT potentially_RB valuable_JJ drug_NN for_IN the_DT treatment_NN of_IN invasive_JJ mycoses_NNS in_IN transplant_NN recipients_NNS ._SENT Antifungal_JJ agents_NNS are_VBP known_VBN to_TO inhibit_VB cytochrome_NN P450_NP 3A4/5_NP (_( CYP3A4/5_NP )_) enzymes_NNS ._SENT CYP3A4/5_NP is_VBZ also_RB involved_VBN in_IN the_DT metabolism_NN of_IN cyclosporine_NN ,_, tacrolimus_NN ,_, and_CC sirolimus_NN ._SENT Preliminary_JJ observations_NNS indicate_VBP that_IN voriconazole_NN at_IN a_DT dose_NN of_IN 200_CD mg_NN twice_RB a_DT day_NN increases_VBZ the_DT trough_NN concentrations_NNS in_IN blood_NN of_IN cyclosporine_NN in_IN transplant_NN patients_NNS (_( P._NP Ghahramani_NP ,_, A._NP J._NP Romero_NP ,_, A._NP F._NP Lant_NP ,_, and_CC M._NP J._NP Allen_NP ,_, Abstr_NP ._SENT 40th_JJ Intersci_NP ._SENT Conf_NP ._SENT Antimicrob_NN ._SENT Agents_NPS Chemother_NP ._SENT ,_, abstr_NN ._SENT 845_CD ,_, p._NN 24_CD ,_, 2000_CD )_) ._SENT We_PP hypothesized_VBD that_IN voriconazole_NN will_MD alter_VB the_DT hepatic_JJ metabolism_NN of_IN tacrolimus_NN as_IN well_RB ._SENT The_DT objectives_NNS of_IN the_DT present_JJ study_NN were_VBD to_TO evaluate_VB the_DT interaction_NN between_IN voriconazole_NN and_CC tacrolimus_NN clinically_RB in_IN transplant_NN patients_NNS and_CC in_IN vitro_NN by_IN using_VBG human_JJ liver_NN microsomes_NNS ._SENT (_( These_DT data_NNS were_VBD presented_VBN in_IN part_NN at_IN the_DT 41st_JJ Interscience_NN Conference_NN on_IN Antimicrobial_JJ Agents_NNS and_CC Chemotherapy_NN ,_, Chicago_NP ,_, Ill._NP ,_, 16_CD to_TO 19_CD December_NP 2001_CD ._SENT )_) The_DT clinical_JJ study_NN was_VBD designed_VBN as_IN an_DT open-labeled_NN ,_, randomized_VBD ,_, two-period_NN ,_, two-treatment_NN ,_, placebo-controlled_VBN pharmacokinetic_JJ study_NN in_IN liver_JJR transplant_NN recipients_NNS ._SENT The_DT study_NN protocol_NN was_VBD approved_VBN by_IN the_DT Institutional_NP Review_NP Board_NP of_IN the_DT VA_NP Medical_NP Center_NP ._SENT Informed_JJ consent_NN was_VBD obtained_VBN from_IN the_DT study_NN participants_NNS ._SENT Prior_RB to_TO enrollment_NN ,_, patients_NNS were_VBD to_TO be_VB stabilized_VBN for_IN at_IN least_JJS 1_CD week_NN on_IN their_PP$ present_JJ dose_NN of_IN tacrolimus_NN ._SENT The_DT first_JJ patient_NN was_VBD randomized_VBN to_TO voriconazole_NN ,_, and_CC the_DT second_JJ patient_NN was_VBD randomized_VBN to_TO placebo_NN ._SENT Concurrent_JJ medications_NNS in_IN patient_JJ 1_CD included_VBD fludrocortisone_NN ,_, insulin_NN ,_, and_CC magnesium_NN antacids_NNS ,_, and_CC those_DT in_IN patient_JJ 2_CD included_VBD felodipine_NN ,_, fludrocortisone_NN ,_, trimethoprim-sulfamethoxazole_NN ,_, and_CC magnesium_NN antacids_NNS ._SENT Tacrolimus_NN concentrations_NNS were_VBD measured_VBN by_IN a_DT microparticulate_JJ enzyme_NN immunoassay_NN (_( MEIA_NP )_) ._SENT Due_JJ to_TO a_DT significant_JJ increase_NN in_IN the_DT trough_NN tacrolimus_NN blood_NN concentrations_NNS in_IN the_DT first_JJ patient_NN during_IN the_DT first_JJ few_JJ days_NNS after_IN administration_NN of_IN voriconazole_NN ,_, the_DT study_NN was_VBD discontinued_VBN ._SENT Table_NN describes_VBZ the_DT dosing_VBG regimen_NN of_IN voriconazole_NN and_CC tacrolimus_NN and_CC the_DT concentrations_NNS of_IN tacrolimus_NN in_IN blood_NN in_IN the_DT two_CD subjects_NNS who_WP participated_VBD in_IN the_DT study_NN ._SENT The_DT concentration_NN of_IN tacrolimus_NN increased_VBD nearly_RB 10-fold_NN in_IN the_DT patient_NN who_WP received_VBD voriconazole_NN ._SENT Voriconazole_NP was_VBD discontinued_VBN and_CC tacrolimus_NN was_VBD withheld_VBN until_IN the_DT levels_NNS in_IN blood_NN returned_VBN to_TO baseline_JJ values_NNS ._SENT TABLE_NN 1_CD |_SYM Clinical_JJ pharmacokinetic_JJ study_NN summary_NN Human_JJ liver_NN microsomes_NNS are_VBP commonly_RB used_VBN to_TO assess_VB drug_NN metabolism_NN and_CC drug-drug_NN interactions_NNS ._SENT A_DT human_JJ liver_NN microsome_NN was_VBD prepared_VBN by_IN differential_JJ centrifugation_NN from_IN liver_NN that_WDT was_VBD not_RB used_VBN for_IN organ_NN transplantation_NN ._SENT To_TO evaluate_VB the_DT 50_CD %_NN inhibitory_JJ concentration_NN (_( IC50_NP )_) of_IN voriconazole_NN ,_, tacrolimus_NNS (_( 50_CD ng/ml_NNS )_) and_CC voriconazole_NN (_( 0_CD to_TO 100_CD mug/ml_NN )_) were_VBD incubated_VBN with_IN microsomal_JJ protein_NN (_( 0.02_CD to_TO 0.08_CD mg/ml_NN )_) in_IN the_DT presence_NN of_IN MgCl2_NP (_( 10_CD mM_NNS )_) for_IN 10_CD min_NN at_IN 37C_JJ in_IN 0.1_CD mM_NP phosphate_NN buffer_NN (_( pH_NN 7.4_CD )_) ._SENT The_DT metabolism_NN of_IN tacrolimus_NN was_VBD initiated_VBN with_IN the_DT addition_NN of_IN NADPH_NP (_( 1_CD mM_NNS )_) ._SENT After_IN 15_CD min_NN ,_, the_DT reaction_NN was_VBD terminated_VBN by_IN placing_VBG the_DT tubes_NNS into_IN ice_NN ._SENT Tacrolimus_NN concentrations_NNS were_VBD measured_VBN immediately_RB by_IN a_DT minor_JJ modification_NN of_IN the_DT MEIA_NP method_NN used_VBN for_IN blood_NN samples_NNS ._SENT For_IN the_DT calculation_NN of_IN Vmax_NP (_( maximal_JJ velocity_NN of_IN tacrolimus_NN metabolism_NN )_) and_CC Km_NP values_NNS (_( the_DT affinity_NN of_IN tacrolimus_NN for_IN the_DT enzyme_NN )_) ,_, tacrolimus_NN was_VBD incubated_VBN at_IN various_JJ concentrations_NNS (_( 0_CD to_TO 20_CD muM_NN )_) in_IN the_DT absence_NN and_CC in_IN the_DT presence_NN of_IN 200_CD mug_NN of_IN voriconazole/ml_NN ._SENT Tacrolimus_NNS with_IN and_CC without_IN voriconazole_NN was_VBD incubated_VBN with_IN a_DT human_JJ liver_NN microsome_NN at_IN a_DT protein_NN concentration_NN of_IN 0.4_CD mg/ml_NN ,_, in_IN the_DT presence_NN of_IN MgCl2_NP (_( 10_CD mM_NNS )_) for_IN 10_CD min_NN at_IN 37C_JJ in_IN 0.1_CD mM_NP phosphate_NN buffer_NN (_( pH_NN 7.4_CD )_) ._SENT The_DT metabolism_NN of_IN tacrolimus_NN was_VBD initiated_VBN with_IN the_DT addition_NN of_IN NADPH_NP (_( 1_CD mM_NNS )_) ._SENT After_IN 30_CD min_NN ,_, the_DT reaction_NN was_VBD terminated_VBN by_IN placing_VBG the_DT tubes_NNS into_IN ice_NN ._SENT The_DT tacrolimus_NN concentration_NN was_VBD measured_VBN by_IN high-pressure_JJ liquid_JJ chromatography_NN (_( HPLC_NP )_) ._SENT For_IN HPLC_NP analysis_NN ,_, 5_CD ml_NN of_IN cold_JJ ethyl_NN ether_NN was_VBD added_VBN to_TO the_DT cooled_VBN microsome_NN ._SENT Cyclosporine_NN (_( 50_CD mul_NN of_IN a_DT 0.1-mg/ml_NN concentration_NN in_IN methanol_NN )_) was_VBD added_VBN as_IN the_DT internal_JJ standard_NN ._SENT Tacrolimus_NN and_CC cyclosporine_NN were_VBD extracted_VBN into_IN ethyl_NN ether_NN ,_, and_CC the_DT ether_NN layer_NN was_VBD separated_VBN and_CC evaporated_VBN under_IN nitrogen_NN ._SENT The_DT residue_NN obtained_VBN was_VBD reconstituted_VBN in_IN acetonitrile-H2O_NN (_( 6:4_CD )_) for_IN HPLC_NP analysis_NN ._SENT The_DT change_NN in_IN the_DT concentration_NN of_IN tacrolimus_NN was_VBD quantified_VBN by_IN reverse-phase_JJ HPLC_NP ._SENT A_DT C18_NP column_NN (_( 3.9_CD by_IN 150_CD mm_NN ;_: 10_CD mum_NN ;_: Bondapack_NP ;_: part_NN no_RB ._SENT 86684_LS )_) was_VBD equipped_VBN with_IN a_DT C18_NP guard_NN column_NN and_CC maintained_VBN at_IN 70C_NP ._SENT A_DT mobile_JJ phase_NN consisting_VBG of_IN acetonitrile-water_NN (_( 6:4_CD )_) at_IN a_DT flow_NN rate_NN of_IN 1.5_CD ml/min_NN was_VBD used_VBN ._SENT Tacrolimus_NP eluted_VBD at_IN 4.5_CD min_NN ,_, and_CC cyclosporine_NN eluted_VBN at_IN 7.0_CD min_NN ._SENT The_DT column_NN eluent_NN was_VBD monitored_VBN at_IN 214_CD nm_NN ._SENT The_DT concentration_NN of_IN voriconazole_NN necessary_JJ to_TO inhibit_VB the_DT metabolism_NN of_IN tacrolimus_NN by_IN 50_CD %_NN was_VBD calculated_VBN as_IN the_DT IC50_NP ._SENT IC50_NP ,_, Vmax_NP ,_, and_CC Km_NP were_VBD calculated_VBN with_IN Prism_NN software_NN (_( GraphPad_NP Software_NP Inc._NP )_) ._SENT In_IN three_CD different_JJ sets_NNS of_IN microsomes_NNS ,_, the_DT mean_JJ (_( +-_NN standard_NN deviation_NN )_) concentration_NN of_IN voriconazole_NN needed_VBN to_TO inhibit_VB the_DT metabolism_NN of_IN tacrolimus_NN by_IN 50_CD %_NN was_VBD 10.4_CD +-_NN 4.3_CD mug/ml_NN ._SENT The_DT Vmax_NP and_CC Km_NP for_IN tacrolimus_NN metabolism_NN were_VBD 1.47_CD nmol/min/mg_NN of_IN protein_NN and_CC 10.64_CD muM_NN in_IN the_DT absence_NN and_CC 0.37_CD nmol/min/mg_NN of_IN protein_NN and_CC 5.43_CD muM_NN in_IN the_DT presence_NN of_IN voriconazole_NN ,_, respectively_RB ._SENT This_DT suggests_VBZ that_IN voriconazole_NN inhibits_VBZ the_DT metabolism_NN of_IN tacrolimus_NN by_IN competitive_JJ and_CC noncompetitive_JJ mechanisms_NNS ._SENT The_DT in_IN vitro_NN study_NN qualitatively_RB predicted_VBD the_DT in_IN vivo_JJ interaction_NN between_IN tacrolimus_NN and_CC voriconazole_NN ._SENT However_RB ,_, the_DT magnitude_NN of_IN the_DT observed_VBN in_IN vivo_JJ inhibition_NN of_IN tacrolimus_NN metabolism_NN appeared_VBD to_TO be_VB much_RB greater_JJR than_IN predicted_VBN based_VBN on_IN the_DT in_IN vitro_NN studies_NNS using_VBG concentrations_NNS of_IN voriconazole_NN comparable_JJ to_TO those_DT documented_VBN clinically_RB in_IN the_DT serum_NN ._SENT These_DT data_NNS suggest_VBP that_IN voriconazole_NN may_MD be_VB present_JJ in_IN higher_JJR concentrations_NNS in_IN the_DT gut_NN and_CC may_MD inhibit_VB gut_NN metabolism_NN of_IN tacrolimus_NN ,_, thereby_RB increasing_VBG the_DT oral_JJ bioavailability_NN of_IN tacrolimus_NN beyond_IN its_PP$ inhibitory_JJ effect_NN on_IN the_DT hepatic_JJ metabolism_NN of_IN tacrolimus_NN ,_, as_RB has_VBZ been_VBN shown_VBN elsewhere_RB for_IN the_DT interaction_NN between_IN ketoconazole_NN and_CC cyclosporine-tacrolimus_NN ._SENT In_IN conclusion_NN ,_, coadministration_NN of_IN voriconazole_NN and_CC tacrolimus_NN resulted_VBN in_IN a_DT significant_JJ increase_NN in_IN the_DT trough_NN concentrations_NNS of_IN tacrolimus_NN in_IN blood_NN ._SENT The_DT in_IN vitro_NP human_JJ liver_NN microsomal_JJ study_NN documented_VBD that_IN ,_, at_IN clinically_RB relevant_JJ concentrations_NNS of_IN voriconazole_NN ,_, the_DT metabolism_NN of_IN tacrolimus_NN was_VBD inhibited_VBN ._SENT Monitoring_VBG of_IN blood_NN levels_NNS of_IN tacrolimus_NN and_CC adjustment_NN in_IN its_PP$ dosage_NN are_VBP warranted_VBN in_IN transplant_NN patients_NNS receiving_VBG voriconazole_NN ._SENT FIG._NN 1_CD ._SENT |_SYM Effect_NN of_IN voriconazole_NN on_IN tacrolimus_NN metabolism_NN ._SENT Effect_NN of_IN voriconazole_NN on_IN tacrolimus_NN metabolism_NN ._SENT Tacrolimus_NP (_( 50_CD ng/ml_NNS )_) was_VBD incubated_VBN in_IN the_DT presence_NN of_IN various_JJ concentrations_NNS of_IN voriconazole_NN (_( 0_CD to_TO 100_CD mug/ml_NN )_) ._SENT The_DT amount_NN of_IN tacrolimus_NNS metabolized_VBN per_IN time_NN in_IN the_DT absence_NN and_CC in_IN the_DT presence_NN of_IN various_JJ concentrations_NNS of_IN voriconazole_NN was_VBD measured_VBN by_IN MEIA_NP ._SENT At_IN a_DT concentration_NN of_IN 6.3_CD mug/ml_NN ,_, voriconazole_NN inhibits_VBZ the_DT metabolism_NN of_IN tacrolimus_NN by_IN 50_CD %_NN in_IN one_CD microsome_NN sample_NN ._SENT FIG._NN 2_CD ._SENT |_SYM Metabolism_NN of_IN tacrolimus_NN in_IN the_DT presence_NN of_IN voriconazole_NN ._SENT Metabolism_NN of_IN tacrolimus_NN in_IN the_DT presence_NN of_IN voriconazole_NN ._SENT Tacrolimus_NP (_( 0_CD to_TO 20_CD muM_NN )_) was_VBD incubated_VBN in_IN the_DT absence_NN (_( *_SYM )_) or_CC in_IN the_DT presence_NN of_IN 200_CD mug_NN of_IN voriconazole/ml_NN ,_, and_CC the_DT amount_NN of_IN tacrolimus_NNS metabolized_VBN was_VBD estimated_VBN by_IN HPLC_NP ._SENT The_DT figure_NN shows_VBZ that_IN voriconazole_NN decreases_VBZ the_DT maximal_JJ velocity_NN of_IN tacrolimus_NN metabolism_NN (_( Vmax_NP ,_, 1.47_CD to_TO 0.37_CD nmol/min/mg_NN of_IN protein_NN )_) and_CC changes_VBZ the_DT affinity_NN of_IN tacrolimus_NN for_IN the_DT enzyme_NN (_( Km_NP ,_, 10.64_CD to_TO 5.43_CD muM_NN )_) ._SENT 